iPower and Savara Shares Climb on Supply Chain and FDA Milestones

Strategic Shifts and Regulatory Wins

iPower Inc. announced a significant overhaul of its logistics operations, moving to consolidate its vendor base and transition toward U.S.-based sourcing. The strategic pivot aims to streamline the company's supply chain amid broader industry shifts toward domestic production. Following the announcement, iPower shares rallied 5% to $3.42, recovering from a 3.3% dip during Friday’s session.

Meanwhile, Savara Inc. secured a critical regulatory milestone as the Food and Drug Administration (FDA) granted priority review for its Molbreevi application. This designation typically accelerates the evaluation process for drugs that offer significant improvements in safety or effectiveness for serious conditions. Investors responded positively to the news, sending the stock up 3.6% in early trading.

Both companies are attempting to regain momentum after closing in the red at the end of last week. The positive market reaction highlights a continued investor focus on operational efficiency in the retail sector and clinical progress within the biotech industry. According to market data, the gains effectively erased the losses sustained by both entities during the previous Friday's trading session.